{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:39:31Z","timestamp":1776400771824,"version":"3.51.2"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T05:53:47Z","timestamp":1753077227000},"page":"e950-e960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Relapsed\/Refractory Myeloma in Resource Constrained Setting"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8004-5270","authenticated-orcid":false,"given":"L. Rohit","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-2500","authenticated-orcid":false,"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandraprakash","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2025.07.007_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.07.007_bib0002","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.07.007_bib0003","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1182\/bloodadvances.2024014723","article-title":"Retreatment of multiple myeloma with previously refractory drugs","volume":"8","author":"Goel","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.07.007_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0609.2000.9r233.x","article-title":"Novel therapeutic targets in multiple myeloma","volume":"64","author":"Davies","year":"2000","journal-title":"Eur J Haematol"},{"issue":"38","key":"10.1016\/j.clml.2025.07.007_bib0005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035319","article-title":"Efficacy and safety of daratumumab in the treatment of relapsed\/refractory multiple myeloma: a meta-analysis of randomized controlled trials","volume":"102","author":"Huang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.clml.2025.07.007_bib0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/fon-2023-0842","article-title":"Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study","volume":"20","author":"Kumar","year":"2024","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.07.007_bib0007","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.07.007_bib0008","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.007_bib0009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2021.01.018","article-title":"Real-world treatment of patients with relapsed\/refractory myeloma","volume":"21","author":"Ntanasis-Stathopoulos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.07.007_bib0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12185-021-03204-9","article-title":"Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial","volume":"114","author":"Suzuki","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.clml.2025.07.007_bib0011","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0846","article-title":"Practice patterns and outcomes for triple-class exposed patients with relapsed\/refractory multiple myeloma in Japan","author":"Iida","year":"2022","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.07.007_bib0012","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjh.18200","article-title":"Bendamustine in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a phase II trial","volume":"198","author":"Kumar","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.07.007_bib0013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/GO.20.00228","article-title":"Real-world outcomes with generic pomalidomide in relapsed refractory multiple myeloma-experience from a tertiary care cancer center","volume":"7","author":"Bondili","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.07.007_bib0014","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.007_bib0015","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijmr.IJMR_1593_18","article-title":"High dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome","volume":"149","author":"Kumar","year":"2019","journal-title":"Indian J Med Res"},{"issue":"9","key":"10.1016\/j.clml.2025.07.007_bib0016","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.07.007_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2025.07.007_bib0018","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fernandez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.07.007_bib0019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.clml.2025.07.007_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bmt.1703093","article-title":"Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria","volume":"28","author":"Sirohi","year":"2001","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.clml.2025.07.007_bib0021","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.007_bib0022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.07.007_bib0023","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2025.07.007_bib0024","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.26439","article-title":"Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome","volume":"97","author":"Kaddoura","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.007_bib0025","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.clml.2025.07.007_bib0026","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41375-018-0271-1","article-title":"Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse","volume":"33","author":"Sidana","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.07.007_bib0027","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2022007082","article-title":"Outcomes after biochemical or clinical progression in patients with multiple myeloma","volume":"7","author":"Goldman-Mazur","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.07.007_bib0028","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2025.07.007_bib0029","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood.2020008734","article-title":"How I treat relapsed multiple myeloma","volume":"139","author":"Kastritis","year":"2022","journal-title":"Blood"},{"issue":"10068","key":"10.1016\/j.clml.2025.07.007_bib0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2025.07.007_bib0031","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40258-024-00877-1","article-title":"Cost-effectiveness of novel agent regimens for transplant-eligible newly diagnosed multiple myeloma patients in India","volume":"22","author":"Dixit","year":"2024","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:39:45Z","timestamp":1776397185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025002526"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Relapsed\/Refractory Myeloma in Resource Constrained Setting","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}